Compare · CELL vs DFTX
CELL vs DFTX
Side-by-side comparison of PhenomeX Inc. (CELL) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $5.14B.
- DFTX has hit the wire 7 times in the past 4 weeks while CELL has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Definium Therapeutics Inc.
- Price
- $1.00+0.14%
- $38.05-0.39%
- Market cap
- -
- $5.14B
- 1M return
- -
- -15.75%
- 1Y return
- -
- +289.26%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 7
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)